ID   BB49-HNC
AC   CVCL_1077
SY   BB49 HNC; BB49HNC; BB49-SCCHN
DR   CLO; CLO_0009940
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1077
DR   Cell_Model_Passport; SIDM00174
DR   ChEMBL-Cells; CHEMBL3308282
DR   ChEMBL-Targets; CHEMBL2366295
DR   Cosmic; 753532
DR   Cosmic; 2116768
DR   Cosmic-CLP; 753532
DR   DepMap; ACH-002213
DR   EGA; EGAS00001000978
DR   GDSC; 753532
DR   GEO; GSM1669608
DR   IARC_TP53; 21187
DR   LINCS_LDP; LCL-1574
DR   PharmacoDB; BB49HNC_75_2019
DR   PubChem_Cell_line; CVCL_1077
DR   Wikidata; Q54795063
RX   PubMed=9271594;
RX   PubMed=11751535;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.66%; Native American=0.55%; East Asian, North=0.98%; East Asian, South=0%; South Asian=2.14%; European, North=57.6%; European, South=38.06% (PubMed=30894373).
ST   Source(s): Cosmic-CLP=753532
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,11
ST   D16S539: 12
ST   D5S818: 12
ST   D7S820: 9,12
ST   TH01: 6
ST   TPOX: 7,9
ST   vWA: 15,19
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VU51 ! BB49-EBV
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 31
//
RX   PubMed=9271594; DOI=10.1084/jem.186.5.785;
RA   Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P.;
RT   "A CASP-8 mutation recognized by cytolytic T lymphocytes on a human
RT   head and neck carcinoma.";
RL   J. Exp. Med. 186:785-793(1997).
//
RX   PubMed=11751535; DOI=10.1093/clinchem/48.1.25;
RA   Zammatteo N., Lockman L., Brasseur F., De Plaen E., Lurquin C.,
RA   Lobert P.-E., Hamels S., Boon T., Remacle J.;
RT   "DNA microarray to monitor the expression of MAGE-A genes.";
RL   Clin. Chem. 48:25-34(2002).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//